⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780268 | 1.00 | — | — | |
| SCHEMBL4500207 | 0.74 | — | — | |
| SCHEMBL11712655 | 0.71 | — | — | |
| SCHEMBL18321042 | 0.70 | — | — | |
| SCHEMBL7336241 | 0.70 | — | — | |
| SCHEMBL27569094 | 0.67 | — | — | |
| SCHEMBL7438630 | 0.67 | — | — | |
| SCHEMBL7438643 | 0.67 | — | — | |
| SCHEMBL7438638 | 0.67 | — | — | |
| SCHEMBL4795496 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | claimed |
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. | 2017-04-20 | — | — | US | claimed |
| EP-3148538-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | Tobira Therapeutics, Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2016123541-A2 | CENICRIVIROC FOR THE TREATMENT OF ENCEPHALITIS INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | claimed |
| WO-2015187663-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| US-8362058-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | claimed |
| JP-56083477-A | — | — | None | — | — | JP | disclosed |
| CN-113329746-B | Compounds for the treatment or prophylaxis of pain, inflammation and/or autoimmunity | 诺瓦麦有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-108743549-B | Self-regulating release of active pharmaceutical ingredient | 阿库拉制药公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117899209-A | Vaccination and antibody production platform | 德国癌症研究公共权益基金会 | 2024-04-19 | — | — | CN | disclosed |
| CN-117279681-A | Product delivery device and method | 呼吸解决方案股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116322655-A | Soft gel capsule for regulating release | R·P·谢勒技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| CN-1404461-A | Process for producing cyclic compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-03-19 | — | — | CN | disclosed |
| US-5814642-A | CHOLINESTERASE INHIBITORY COMPOSITION FOR TREATMENT OF SENILE DEMENTIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-29 | — | — | US | disclosed |
| JP-S5683477-A | 1-BENZAZOCINE DERIVATIVE | SENDAI FUKUSOKAN KAGAKU KENKYUSHO | 1981-07-08 | — | — | JP | disclosed |